{"generic":"Nabilone","drugs":["Cesamet","Nabilone"],"mono":{"0":{"id":"389570-s-0","title":"Generic Names","mono":"Nabilone"},"1":{"id":"389570-s-1","title":"Dosing and Indications","sub":{"0":{"id":"389570-s-1-4","title":"Adult Dosing","mono":"<b>Chemotherapy-induced nausea and vomiting, in patients who fail to respond adequately to other antiemetic agents:<\/b> 1 to 2 mg ORALLY twice daily; first dose should be given 1 to 3 hours before chemotherapy; start with 1 mg to minimize side effects and increase dose as necessary; may also be helpful to administer 1 or 2 mg the night prior to chemotherapy; may be administered 2 or 3 times daily during the entire course of each cycle of chemotherapy; if required, continue up to 48 hours after the last dose of chemotherapy; MAX 6 mg a day in 3 divided doses "},"1":{"id":"389570-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in children younger than 18 years of age "},"3":{"id":"389570-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Chemotherapy-induced nausea and vomiting, in patients who fail to respond adequately to other antiemetic agents<br\/>"}}},"3":{"id":"389570-s-3","title":"Contraindications\/Warnings","sub":[{"id":"389570-s-3-9","title":"Contraindications","mono":"hypersensitivity to marijuana or other cannabinoids <br\/>"},{"id":"389570-s-3-10","title":"Precautions","mono":"<ul><li>central nervous system effects can occur; may be persistent (up to 72 hours) and unpredictable<\/li><li>concomitant use of central nervous system depressants or other psychoactive drugs; additive or synergistic effects may occur<\/li><li>elderly patients; increased risk of postural hypotension<\/li><li>heart disease; increased risk of postural hypotension<\/li><li>hepatic dysfunction<\/li><li>hypertension; increased risk of postural hypotension<\/li><li>orthostatic hypotension may occur<\/li><li>potential for abuse or dependence; prescriptions should be limited to the smallest amount needed for a single course of chemotherapy<\/li><li>psychiatric disorders, current or history; use may unmask symptoms of disorders such as manic depression, depression, and schizophrenia<\/li><li>substance abuse, history<\/li><li>tachycardia may occur<\/li><\/ul>"},{"id":"389570-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"389570-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"389570-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension (8%)<\/li><li><b>Gastrointestinal:<\/b>Xerostomia (22% to 36%)<\/li><li><b>Neurologic:<\/b>Asthenia (8%), Ataxia (13% to 14%), Dyssomnia (11%), Headache (6% to 7%), Poor concentration (12%), Somnolence (52% to 66%), Vertigo (52% to 59%)<\/li><li><b>Ophthalmic:<\/b>Visual disturbance (13%)<\/li><li><b>Psychiatric:<\/b>Dysphoric mood (9%)<\/li><li><b>Other:<\/b>Euphoria (11% to 38%)<\/li><\/ul><b>Serious<\/b><br\/><b>Psychiatric:<\/b>Psychotic disorder<br\/>"},"6":{"id":"389570-s-6","title":"Drug Name Info","sub":{"0":{"id":"389570-s-6-17","title":"US Trade Names","mono":"Cesamet<br\/>"},"2":{"id":"389570-s-6-19","title":"Class","mono":"<ul><li>Antiemetic<\/li><li>Cannabinoid<\/li><\/ul>"},"3":{"id":"389570-s-6-20","title":"Regulatory Status","mono":"Schedule II<br\/>"},"4":{"id":"389570-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"8":{"id":"389570-s-8","title":"Pharmacokinetics","sub":[{"id":"389570-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, 2 h<\/li><li>Bioavailability: 95.6% to 100%<\/li><li>Effect of food: none<\/li><\/ul>"},{"id":"389570-s-8-24","title":"Distribution","mono":"Vd, 12.5 L\/kg <br\/>"},{"id":"389570-s-8-25","title":"Metabolism","mono":"Hepatic, extensive <br\/>"},{"id":"389570-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 60% to 65% as metabolites or unchanged<\/li><li>Renal: 20% to 24% as metabolites or unchanged<\/li><\/ul>"},{"id":"389570-s-8-27","title":"Elimination Half Life","mono":"2 hours <br\/>"}]},"10":{"id":"389570-s-10","title":"Monitoring","mono":"signs of excessive use, abuse, and misuse <br\/>"},"11":{"id":"389570-s-11","title":"How Supplied","mono":"<b>Cesamet<\/b><br\/>Oral Capsule: 1 MG<br\/>"},"13":{"id":"389570-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause poor concentration or somnolence.<\/li><li>Instruct patient to rise slowly from a sitting\/supine position, as drug may cause orthostatic hypotension. Patients who are elderly or those having heart disease or hypertension may be at higher risk for this effect.<\/li><li>This drug may cause xerostomia, asthenia, ataxia, dyssomnia, headache, vertigo, visual disturbance, dysphoric mood, or euphoria.<\/li><li>Drug may cause or unmask symptoms of psychotic disorder. Instruct patient to report worsening depression, suicidal ideation, or unusual changes in behavior.<\/li><li>Instruct patient to not drink alcohol or use CNS depressants or other psychoactive drugs while taking this drug, as this may cause additive or synergistic effects.<\/li><\/ul>"}}}